Liqiang Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Liqiang Yang has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Chengxiang Wang
Guangxi University of Chinese Medicine, Nanning, China
2 shared publicationsChuncheng Zheng
Guangxi University of Chinese Medicine, Nanning, China
2 shared publicationsGe Wu
Guangxi University of Chinese Medicine, Nanning, China
2 shared publicationsPengyun Kong
Guangxi University of Chinese Medicine, Nanning, China
2 shared publicationsPing Yang
Guangxi University of Chinese Medicine, Nanning, China
2 shared publications- Xiaohong Li
Guangxi University of Chinese Medicine, Nanning, China
2 shared publications
Latest Publications
- Open Access
- 25 September 2025
- Published by Springer Nature in BMC Microbiology
- Vol. 25 (1) , 1-15
Gut microbiota dysbiosis promotes coronary heart disease comorbid with depression through lipopolysaccharides and Toll-like receptor 4
Coronary heart disease (CHD) and depression often coexist and complicate patient care. The gut microbiota plays a crucial role in overall health and is involved in both conditions. Dysbiosis, particularly, increased levels of lipopolysaccharides (LPSs), can activate the Toll-like receptor 4 (TLR4), triggering inflammatory pathways associated with CHD and depression. Although some associations have been observed, the direct mechanistic association among gut dysbiosis, LPSs, TLR4 activation, and comorbidity of CHD and depression remains unclear. Thus, in the present study, we aimed to explore this association and the potential of modulating gut microbiota as a therapeutic strategy. A rat model of CHD and depression was established using a high-fat diet and chronic unpredictable mild stress and verified by electrocardiogram, behavioral assessments, and cardiac marker analysis. Fecal microbiota transplantation (FMT) was performed by transferring microbiota from diseased rats to healthy rats (FMT-Disease group); the fecal microbiota of the rats from the FMT-Disease and FMT-Normal groups were compared. The TLR4 inhibitor TAK-242 was administered, creating the Disease + TAK-242 and FMT-Disease-TAK-242 groups. Gut microbiota composition was analyzed using 16 S rRNA high-throughput sequencing; LPS levels were measured using enzyme-linked immunosorbent assay. Polymerase chain reaction and western blotting were used to detect the expression of genes and proteins related to the TLR4/MYD88/NF-κB pathway in the heart and hippocampus, respectively. We confirmed that in the FMT-Disease group, the gut microbiota of diseased rats altered the gut microbial composition of healthy rats in terms of β-diversity, α-diversity, and community structure. Notably, LPS levels in the serum of FMT-Disease rats were elevated, thereby activating the TLR4/MYD88/NF-κB inflammatory pathway and increasing susceptibility to CHD comorbid with depression. Additionally, after receiving fecal microbiota from healthy rats, the Disease group showed a restoration of gut microbiota balance, improvement in general condition, and normalization of pathological, biochemical, and inflammatory indicators, indicating a suppressive effect on the progression of CHD with depression. Our findings further clarify the interrelationship between gut microbiota and CHD comorbid with depression, enhancing our understanding of its pathogenesis. Moreover, we propose a potential novel therapeutic strategy that focuses on modulating gut microbiota composition to block the TLR4/MYD88/NF-κB inflammatory pathway.
- 25 September 2025
- Published by Springer Nature in BMC Microbiology
- Vol. 25 (1) , 1-15
Open AccessGut microbiota dysbiosis promotes coronary heart disease comorbid with depression through lipopolysaccharides and Toll-like receptor 4
Coronary heart disease (CHD) and depression often coexist and complicate patient care. The gut microbiota plays a crucial role in overall health and is involved in both conditions. Dysbiosis, particularly, increased levels of lipopolysaccharides (LPSs), can activate the Toll-like receptor 4 (TLR4), triggering inflammatory pathways associated with CHD and depression. Although some associations have been observed, the direct mechanistic association among gut dysbiosis, LPSs, TLR4 activation, and comorbidity of CHD and depression remains unclear. Thus, in the present study, we aimed to explore this association and the potential of modulating gut microbiota as a therapeutic strategy. A rat model of CHD and depression was established using a high-fat diet and chronic unpredictable mild stress and verified by electrocardiogram, behavioral assessments, and cardiac marker analysis. Fecal microbiota transplantation (FMT) was performed by transferring microbiota from diseased rats to healthy rats (FMT-Disease group); the fecal microbiota of the rats from the FMT-Disease and FMT-Normal groups were compared. The TLR4 inhibitor TAK-242 was administered, creating the Disease + TAK-242 and FMT-Disease-TAK-242 groups. Gut microbiota composition was analyzed using 16 S rRNA high-throughput sequencing; LPS levels were measured using enzyme-linked immunosorbent assay. Polymerase chain reaction and western blotting were used to detect the expression of genes and proteins related to the TLR4/MYD88/NF-κB pathway in the heart and hippocampus, respectively. We confirmed that in the FMT-Disease group, the gut microbiota of diseased rats altered the gut microbial composition of healthy rats in terms of β-diversity, α-diversity, and community structure. Notably, LPS levels in the serum of FMT-Disease rats were elevated, thereby activating the TLR4/MYD88/NF-κB inflammatory pathway and increasing susceptibility to CHD comorbid with depression. Additionally, after receiving fecal microbiota from healthy rats, the Disease group showed a restoration of gut microbiota balance, improvement in general condition, and normalization of pathological, biochemical, and inflammatory indicators, indicating a suppressive effect on the progression of CHD with depression. Our findings further clarify the interrelationship between gut microbiota and CHD comorbid with depression, enhancing our understanding of its pathogenesis. Moreover, we propose a potential novel therapeutic strategy that focuses on modulating gut microbiota composition to block the TLR4/MYD88/NF-κB inflammatory pathway.
- Open Access
- 28 November 2024
- Published by Springer Nature in Research Square
Gut microbiota dysbiosis promotes coronary heart disease comorbid with depression through lipopolysaccharides and TLR4 receptors
Background: Coronary heart disease (CHD) and depression often coexist, complicating patient care due to their intertwined pathophysiology. Gut microbiota plays a crucial role in overall health and is involved in both conditions. Dysbiosis, especially increased levels of lipopolysaccharides (LPS), can activate the TLR4 receptor, triggering inflammatory pathways linked to CHD and depression. Although some associations have been observed, the direct mechanistic link between gut dysbiosis, LPS, TLR4 activation, and the comorbidity of CHD with depression remains unclear. This study aims to explore this relationship and the potential of gut microbiota modulation as a therapeutic strategy. Methods: A rat model of CHD and depression was established using a high-fat diet and chronic unpredictable mild stress (CUMS), verified by electrocardiogram (ECG), behavioral assessments, and cardiac markers. Fecal microbiota transplantation (FMT) was performed, transferring microbiota from diseased rats to healthy rats (FMT-Disease group), compared to an FMT-Normal group. To explore inflammatory pathways, the TLR4 inhibitor TAK-242 was administered, creating Disease+TAK-242 and FMT-Disease-TAK-242 groups. Blood LPS levels, TLR4/MYD88/NF-κB marker expression in cardiac and hippocampal tissues, and health indicators were evaluated using 16S rRNA sequencing, ELISA, RT-qPCR, and Western blot. Results: Diseased rats showed significantly reduced gut microbiota α- and β-diversity, indicating dysbiosis. FMT from diseased rats increased LPS levels, activated the TLR4/MYD88/NF-κB pathway, and heightened susceptibility to CHD and depression in healthy rats. TAK-242 lowered LPS levels and reduced inflammatory markers, confirming the role of the TLR4 pathway in disease progression. The Disease+Normal FMT group demonstrated improved gut microbiota composition, reduced myocardial damage, and alleviated depressive behaviors, highlighting the therapeutic potential of healthy microbiota transplantation. Conclusion: This study establishes a link between gut dysbiosis and the comorbidity of CHD with depression. Dysbiosis, marked by elevated LPS, activates the TLR4/MYD88/NF-κB pathway, increasing susceptibility to both conditions. FMT from healthy rats alleviated symptoms, suggesting that gut microbiota modulation could be a promising therapeutic strategy for these comorbidities.
- 28 November 2024
- Published by Springer Nature in Research Square
Open AccessGut microbiota dysbiosis promotes coronary heart disease comorbid with depression through lipopolysaccharides and TLR4 receptors
Background: Coronary heart disease (CHD) and depression often coexist, complicating patient care due to their intertwined pathophysiology. Gut microbiota plays a crucial role in overall health and is involved in both conditions. Dysbiosis, especially increased levels of lipopolysaccharides (LPS), can activate the TLR4 receptor, triggering inflammatory pathways linked to CHD and depression. Although some associations have been observed, the direct mechanistic link between gut dysbiosis, LPS, TLR4 activation, and the comorbidity of CHD with depression remains unclear. This study aims to explore this relationship and the potential of gut microbiota modulation as a therapeutic strategy. Methods: A rat model of CHD and depression was established using a high-fat diet and chronic unpredictable mild stress (CUMS), verified by electrocardiogram (ECG), behavioral assessments, and cardiac markers. Fecal microbiota transplantation (FMT) was performed, transferring microbiota from diseased rats to healthy rats (FMT-Disease group), compared to an FMT-Normal group. To explore inflammatory pathways, the TLR4 inhibitor TAK-242 was administered, creating Disease+TAK-242 and FMT-Disease-TAK-242 groups. Blood LPS levels, TLR4/MYD88/NF-κB marker expression in cardiac and hippocampal tissues, and health indicators were evaluated using 16S rRNA sequencing, ELISA, RT-qPCR, and Western blot. Results: Diseased rats showed significantly reduced gut microbiota α- and β-diversity, indicating dysbiosis. FMT from diseased rats increased LPS levels, activated the TLR4/MYD88/NF-κB pathway, and heightened susceptibility to CHD and depression in healthy rats. TAK-242 lowered LPS levels and reduced inflammatory markers, confirming the role of the TLR4 pathway in disease progression. The Disease+Normal FMT group demonstrated improved gut microbiota composition, reduced myocardial damage, and alleviated depressive behaviors, highlighting the therapeutic potential of healthy microbiota transplantation. Conclusion: This study establishes a link between gut dysbiosis and the comorbidity of CHD with depression. Dysbiosis, marked by elevated LPS, activates the TLR4/MYD88/NF-κB pathway, increasing susceptibility to both conditions. FMT from healthy rats alleviated symptoms, suggesting that gut microbiota modulation could be a promising therapeutic strategy for these comorbidities.
- 12 February 2020
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 41 (6) , 735-744
A comparative pharmacogenomic analysis of three classic TCM prescriptions for coronary heart disease based on molecular network modeling
Traditional Chinese medicine (TCM) has evolved over several thousands of years, which has been shown to be efficacious in the treatment of ischemic heart disease. Three classical TCM prescriptions, namely Xuefu Zhuyu Decoction, Zhishi Xiebai Guizhi Decoction, and Gualou Xiebai Banxia Decoction, have been extensively used in the treatment of coronary heart disease (CHD). Based on molecular network modeling, we performed a comparative pharmacogenomic analysis to systematically determine the drug-targeting spectrum of the three prescriptions at molecular level. Wide-area target molecules of CHD were covered, which was a common feature of the three decoctions, demonstrating their therapeutic functions. Meanwhile, collective signaling involved metabolic/pro-metabolic pathways, driving and transferring pathways, neuropsychiatric pathways, and exocrine or endocrine pathways. These organized pharmacological disturbance was mainly focused on almost all stages of CHD intervention, such as anti-atherosclerosis, lipid metabolism, inflammation, vascular wall function, foam cells formation, platelets aggregation, thrombosis, arrhythmia, and ischemia-reperfusion injury. In addition, heterogeneity analysis of the global pharmacological molecular spectrum revealed that signaling crosstalk, cascade convergence, and key targets were tendentious among the three decoctions. After all, it is unadvisable to rank the findings on targeting advantages of the three decoctions. Comparative pharmacological evidence may provide an appropriate decoction scheme for individualized intervention of CHD.
- 12 February 2020
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 41 (6) , 735-744
A comparative pharmacogenomic analysis of three classic TCM prescriptions for coronary heart disease based on molecular network modeling
Traditional Chinese medicine (TCM) has evolved over several thousands of years, which has been shown to be efficacious in the treatment of ischemic heart disease. Three classical TCM prescriptions, namely Xuefu Zhuyu Decoction, Zhishi Xiebai Guizhi Decoction, and Gualou Xiebai Banxia Decoction, have been extensively used in the treatment of coronary heart disease (CHD). Based on molecular network modeling, we performed a comparative pharmacogenomic analysis to systematically determine the drug-targeting spectrum of the three prescriptions at molecular level. Wide-area target molecules of CHD were covered, which was a common feature of the three decoctions, demonstrating their therapeutic functions. Meanwhile, collective signaling involved metabolic/pro-metabolic pathways, driving and transferring pathways, neuropsychiatric pathways, and exocrine or endocrine pathways. These organized pharmacological disturbance was mainly focused on almost all stages of CHD intervention, such as anti-atherosclerosis, lipid metabolism, inflammation, vascular wall function, foam cells formation, platelets aggregation, thrombosis, arrhythmia, and ischemia-reperfusion injury. In addition, heterogeneity analysis of the global pharmacological molecular spectrum revealed that signaling crosstalk, cascade convergence, and key targets were tendentious among the three decoctions. After all, it is unadvisable to rank the findings on targeting advantages of the three decoctions. Comparative pharmacological evidence may provide an appropriate decoction scheme for individualized intervention of CHD.